CNBX Pharmaceuticals Inc (CNBX)
0.0102
0.00 (0.00%)
USD |
OTCM |
May 06, 15:35
CNBX Pharmaceuticals Debt to Equity Ratio: -0.548 for Feb. 29, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| February 29, 2024 | -0.548 |
| November 30, 2023 | -0.6273 |
| August 31, 2023 | -0.666 |
| May 31, 2023 | -0.6979 |
| February 28, 2023 | -0.7653 |
| November 30, 2022 | -0.8931 |
| August 31, 2022 | -1.077 |
| May 31, 2022 | -1.357 |
| February 28, 2022 | -2.045 |
| November 30, 2021 | 1.703 |
| August 31, 2021 | 0.4828 |
| May 31, 2021 | 0.4516 |
| February 28, 2021 | 0.2029 |
| November 30, 2020 | 0.00 |
| August 31, 2020 | 0.00 |
| May 31, 2020 | 0.00 |
| February 29, 2020 | 0.00 |
| Date | Value |
|---|---|
| November 30, 2019 | 0.00 |
| August 31, 2019 | 0.00 |
| May 31, 2019 | 0.00 |
| February 28, 2019 | 0.00 |
| November 30, 2018 | 0.00 |
| August 31, 2018 | 0.00 |
| May 31, 2018 | 0.00 |
| February 28, 2018 | 0.00 |
| November 30, 2017 | 0.00 |
| August 31, 2017 | 0.00 |
| May 31, 2017 | 0.00 |
| February 28, 2017 | 0.00 |
| November 30, 2016 | 0.00 |
| August 31, 2016 | 0.00 |
| May 31, 2016 | 0.00 |
| February 29, 2016 | -0.036 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-2.045
Minimum
Feb 2022
1.703
Maximum
Nov 2021
-0.2918
Average
--
Median
May 2019
Debt to Equity Ratio Benchmarks
| NovaBay Pharmaceuticals Inc | 0.3431 |
| Palatin Technologies Inc | 0.00 |
| iBio Inc | -- |
| Theriva Biologics Inc | -- |
| Oragenics Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 0.1639M |
| Total Liabilities (Quarterly) | 2.522M |
| Shareholders Equity (Quarterly) | -2.358M |
| Current Ratio | 0.065 |
| Net Debt Paydown Yield | 25.21% |